4SC Discovery GmbH
Records under this name other than patents 4SC Discovery GmbH holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 7 of 7 · Back to 4SC Discovery GmbH
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,354,436 | IL17 and Ifn-Gamma Inhibition for the Treatment of Autoimmune Inflammation Formerly held In force · High confidence | In force | High confidence | |
| US 8,592,456 | IL17 and IFN-gamma inhibition for the treatment of autoimmune inflammation Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,005,769 | 2,3-Dihydrobenzofuran-5YL Compounds as Dyrk Kinase Inhibitors Formerly held Lapsed on the fee record Ended Jun 26, 2026 · High confidence | Lapsed on the fee record | Ended Jun 26, 2026 | High confidence |
| US 9,951,050 | Method of inhibiting DYRK1B Formerly held Lapsed on the fee record Ended Apr 24, 2026 · From the USPTO record | Lapsed on the fee record | Ended Apr 24, 2026 | From the USPTO record |
| US 9,580,438 | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders Formerly held Lapsed on the fee record Ended Feb 28, 2025 · From the USPTO record | Lapsed on the fee record | Ended Feb 28, 2025 | From the USPTO record |
| US 10,633,369 | Method of inhibiting DYRK1B Formerly held Lapsed on the fee record Ended Apr 28, 2024 · From the USPTO record | Lapsed on the fee record | Ended Apr 28, 2024 | From the USPTO record |
| US 8,227,516 | Compounds as histone deacetylase inhibitors Lapsed on the fee record Ended Jul 24, 2016 · From the USPTO record | Lapsed on the fee record | Ended Jul 24, 2016 | From the USPTO record |